Drugs / Cangrelor
last change 10 days ago re-read 9 days ago

Cangrelor

Small molecule targets P2RY12 via inhibition

Developed for
coronary artery disorder · acute coronary syndrome · ST-elevation myocardial infarction · atherosclerosis · cardiogenic shock · acute myocardial infarction · cardiac arrest · congenital cardiovascular shunt
+3 more · ischemic disease · myocardial infarction · platelet aggregation, spontaneous
Investigated by
The Medicines Company · University of Florida · Chiesi Farmaceutici S.p.A. · Scott R. MacKenzie Foundation · AHEPA University Hospital · Attikon Hospital
+25 more · BioVendor LM · Changi General Hospital · Charles University, Czech Republic · Chiesi Slovenija, d.o.o. · Faculty Hospital Kralovske Vinohrady · Federico II University · Fondation Ophtalmologique Adolphe de Rothschild · IRCCS San Raffaele · Insel Gruppe AG, University Hospital Bern · Institute of Hematology and Blood Transfusion, Czech Republic · Khaled Ziada, MD · Khoo Teck Puat Hospital · Masaryk University · Ministry of Health, Czech Republic · Ministry of Health, France · National Heart Centre Singapore · National Institute for Metabolic and Cardiovascular Disease Research · National University Hospital, Singapore · Ospedale Santa Croce-Carle Cuneo · Sengkang General Hospital · Tan Tock Seng Hospital · Terumo Medical Corporation · University Hospital, Alexandroupolis · University Hospital, Caen · University Medical Centre Ljubljana

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) KENGREAL — 2015-06-22 fda.gov ↗
Approved EU (EMA) Kengrexal — 2015-03-23 europa.eu ↗

Trials 25

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials · 2 met primary
Phase 1 NCT02765633 Jan 2017 → Aug 2019 congenital cardiovascular shunt Chiesi Farmaceutici S.p.A. Completed Met primary
Phase 1 NCT00699504 Jun → Nov 2008 — The Medicines Company Completed Met primary
Phase 1 NCT00102674 Mar → May 2005 — The Medicines Company Completed No outcome recorded
Phase 27 trials · 1 met primary · 1 missed
Phase 2 NCT06792643 Apr 2024 → Oct 2025 overdue cardiogenic shock, platelet disorder, undefined IRCCS San Raffaele Recruiting No outcome recorded
Phase 2 NCT03862651 Jun 2019 → Dec 2020 platelet aggregation, spontaneous Ospedale Santa Croce-Carle Cuneo Unknown No outcome recorded
Phase 2 NCT03102723 Oct 2017 → Dec 2022 ST-elevation myocardial infarction National Heart Centre Singapore Unknown Missed primary
Phase 2 NCT01979445 Dec 2013 → Jan 2014 coronary artery disorder The Medicines Company Completed No outcome recorded
Phase 2 NCT01852019 Jun → Jul 2013 coronary artery disorder The Medicines Company Completed No outcome recorded
Phase 2 NCT01766466 Jan → Feb 2013 coronary artery disorder The Medicines Company Completed No outcome recorded
Phase 2 NCT00767507 Oct 2008 → Jun 2011 acute coronary syndrome The Medicines Company Completed Met primary
Phase 34 trials · 1 met primary · 2 missed
Phase 3 NCT04667078 Mar 2022 → Dec 2026 ischemic disease Fondation Ophtalmologique Adolphe de Rothschild Suspended No outcome recorded
Phase 3 NCT01156571 Sep 2010 → Dec 2012 acute coronary syndrome, atherosclerosis The Medicines Company Completed Met primary
Phase 3 NCT00385138 Sep 2006 → May 2009 acute coronary syndrome, atherosclerosis The Medicines Company Terminated Missed primary
Phase 3 NCT00305162 Apr 2006 → May 2009 acute coronary syndrome, myocardial infarction The Medicines Company Terminated Missed primary
Phase 411 trials · 2 met primary · 1 missed
Phase 4 NCT07225842 Feb 2026 → Sep 2027 expected coronary artery disorder University of Florida Recruiting No outcome recorded
Phase 4 NCT06089577 Nov 2023 → Oct 2025 overdue coronary artery disorder Federico II University Recruiting No outcome recorded
Phase 4 NCT04927949 Jun 2021 → Mar 2023 ST-elevation myocardial infarction University Hospital, Caen Completed No outcome recorded
Phase 4 NCT04668144 Feb 2021 → Feb 2023 acute coronary syndrome, coronary artery disorder University of Florida Completed Missed primary
Phase 4 NCT04634162 Feb → Aug 2021 coronary artery disorder University of Florida Completed Met primary
Phase 4 NCT04005729 Jul 2019 → Nov 2021 acute coronary syndrome, cardiac arrest University Medical Centre Ljubljana Completed No outcome recorded
Phase 4 NCT03551964 Aug 2018 → Feb 2024 acute myocardial infarction, cardiogenic shock Faculty Hospital Kralovske Vinohrady Completed No outcome recorded
Phase 4 NCT03247738 Nov 2017 → Dec 2018 ST-elevation myocardial infarction University of Florida Completed Met primary
Phase 4 NCT02943369 Jul → Nov 2017 ST-elevation myocardial infarction Attikon Hospital Completed No outcome recorded
Phase 4 NCT02978040 Jul 2017 → Aug 2019 ST-elevation myocardial infarction, coronary artery disorder Insel Gruppe AG, University Hospital Bern Completed Mixed
Comparator or background therapy4 trials
Phase 2 NCT01103440 Comparator Apr 2007 → Jun 2009 — Icahn School of Medicine at Mount Sinai Completed No outcome recorded
Phase 4 NCT03182855 Comparator Sep 2018 → Jun 2019 ST-elevation myocardial infarction, acute coronary syndrome University of Aarhus Unknown No outcome recorded
Phase 4 NCT03273075 Comparator Sep 2017 → May 2021 acute coronary syndrome, cardiac arrest Medical University of Vienna Unknown No outcome recorded
Phase 4 NCT02733341 Comparator Jul 2016 → Oct 2018 ST-elevation myocardial infarction, acute coronary syndrome, vascular occlusion disorder The Royal Wolverhampton Hospitals NHS Trust Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 31 sources stand behind the page.

FieldValueCited text
Known as Cangrelor “Cangrelor” NCT01103440 ↗
28

NCT01979445 ↗

NCT00385138 ↗

NCT02978040 ↗

NCT02943369 ↗

NCT00305162 ↗

NCT01766466 ↗

NCT03247738 ↗

NCT03043274 ↗

NCT07225842 ↗

NCT00699504 ↗

Show 18 more sources

Known as AR-C69931XX ChEMBL registry synonym — accepted as the source's own label CHEMBL334966 ↗
Known as Kangrexal “Cangrelor (Kangrexal) with an i.v. loading bolus (30mg/Kg) followed by i.v. infusion (4mg/Kg/min) for 2 hours.” NCT06089577 ↗
Known as Kengreal ChEMBL registry synonym — accepted as the source's own label CHEMBL334966 ↗
Known as Kengreal (USA) “Cangrelor [Kengrexal (EU), Kengreal (USA)] has been licensed for use in Europe, USA and the UK since March 2015, June 2015 and July 2015 respectively.” NCT02733341 ↗
Known as KENGREXAL (cangrelor) “KENGREXAL® (cangrelor)” NCT03862651 ↗
Known as Kengrexal (EU) “Cangrelor [Kengrexal (EU), Kengreal (USA)] has been licensed for use in Europe, USA and the UK since March 2015, June 2015 and July 2015 respectively.” NCT02733341 ↗
Action Inhibit “is an intravenous blocker of the adenosine diphosphate receptor P2Y(12)” PMID 19915221 ↗ Dec 2009
1

“Purinergic receptor P2Y12 antagonist” CHEMBL334966 ↗

Modality Small molecule “The recently authorized parenteral cangrelor is an adenosine triphosphate (ATP) analogue” NCT03273075 ↗
Route Intravenous “is an intravenous blocker” PMID 19915221 ↗ Dec 2009
Target P2RY12 “Purinergic receptor P2Y12 antagonist” CHEMBL334966 ↗